Proteflazid®:用于治疗疱疹感染的临床和经济依据

I. Zupanets, T. Sakharova
{"title":"Proteflazid®:用于治疗疱疹感染的临床和经济依据","authors":"I. Zupanets, T. Sakharova","doi":"10.24959/CPHJ.16.1396","DOIUrl":null,"url":null,"abstract":"Epidemiological data indicate the widespread dissemination and constant dynamics of the incidence rate of herpesvirus infections due to a variety of forms and transmission paths of the virus, highly contagious and life-long persistence of the herpes virus in the body of the infected persons and the lack of effectiveness of existing treatments. Acyclic guanosine derivatives are the main group of antiviral drugs traditionally used for the causal treatment of herpes infections. They have a number of disadvantages, in particular formation of the virus resistance in a long-term use, the need to involve immunotherapy, as well as the high cost of treatment. The accumulated clinical experience with the original Ukrainian drug Proteflazid® (drops) in treating viral infections, including HHV- infections, shows its high clinical efficacy and safety. A relative estimation of the course treatment costs of herpes-induced infections using antiviral drugs has demonstrated the economic expediency of Proteflazid® with the purpose of treatment and maintenance therapy. Proteflazid® takes the medium sized niche among other antiherpetic drugs. In addition, due to the multi-vector nature of its pharmacodynamic effects (direct antiviral, immunomodulating, interferon-stimulating, antioxidant, apoptosis-modulating, etc.) Proteflazid® allows to exclude antioxidants, immunomodulators from the antiherpetic therapy scheme, or to adjust their use, and it can significantly reduce the cost per a course of treatment.","PeriodicalId":10498,"journal":{"name":"Clinical pharmacy","volume":"7 1","pages":"6-12"},"PeriodicalIF":0.0000,"publicationDate":"2016-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Proteflazid®: clinical and economic substantiation for use in therapy of herpes infection\",\"authors\":\"I. Zupanets, T. Sakharova\",\"doi\":\"10.24959/CPHJ.16.1396\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Epidemiological data indicate the widespread dissemination and constant dynamics of the incidence rate of herpesvirus infections due to a variety of forms and transmission paths of the virus, highly contagious and life-long persistence of the herpes virus in the body of the infected persons and the lack of effectiveness of existing treatments. Acyclic guanosine derivatives are the main group of antiviral drugs traditionally used for the causal treatment of herpes infections. They have a number of disadvantages, in particular formation of the virus resistance in a long-term use, the need to involve immunotherapy, as well as the high cost of treatment. The accumulated clinical experience with the original Ukrainian drug Proteflazid® (drops) in treating viral infections, including HHV- infections, shows its high clinical efficacy and safety. A relative estimation of the course treatment costs of herpes-induced infections using antiviral drugs has demonstrated the economic expediency of Proteflazid® with the purpose of treatment and maintenance therapy. Proteflazid® takes the medium sized niche among other antiherpetic drugs. In addition, due to the multi-vector nature of its pharmacodynamic effects (direct antiviral, immunomodulating, interferon-stimulating, antioxidant, apoptosis-modulating, etc.) Proteflazid® allows to exclude antioxidants, immunomodulators from the antiherpetic therapy scheme, or to adjust their use, and it can significantly reduce the cost per a course of treatment.\",\"PeriodicalId\":10498,\"journal\":{\"name\":\"Clinical pharmacy\",\"volume\":\"7 1\",\"pages\":\"6-12\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-09-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical pharmacy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.24959/CPHJ.16.1396\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24959/CPHJ.16.1396","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

流行病学数据表明,由于疱疹病毒的各种形式和传播途径、疱疹病毒在感染者体内的高度传染性和终身持久性以及现有治疗方法缺乏有效性,疱疹病毒感染的广泛传播和发病率不断变化。无环鸟苷衍生物是传统上用于疱疹感染因果治疗的主要抗病毒药物组。它们有许多缺点,特别是在长期使用中形成病毒耐药性,需要涉及免疫治疗,以及治疗费用高。乌克兰原药Proteflazid®(滴剂)治疗包括HHV感染在内的病毒感染的临床经验表明其具有较高的临床疗效和安全性。对使用抗病毒药物治疗疱疹性感染的疗程费用的相对估计表明,Proteflazid®在治疗和维持治疗方面具有经济上的便利性。Proteflazid®在其他抗疱疹药物中占据中等规模的利基。此外,由于其药效学作用的多载体性质(直接抗病毒、免疫调节、干扰素刺激、抗氧化、细胞凋亡调节等),Proteflazid®允许从抗疱疹治疗方案中排除抗氧化剂、免疫调节剂,或调整其使用,并且可以显着降低每个疗程的成本。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Proteflazid®: clinical and economic substantiation for use in therapy of herpes infection
Epidemiological data indicate the widespread dissemination and constant dynamics of the incidence rate of herpesvirus infections due to a variety of forms and transmission paths of the virus, highly contagious and life-long persistence of the herpes virus in the body of the infected persons and the lack of effectiveness of existing treatments. Acyclic guanosine derivatives are the main group of antiviral drugs traditionally used for the causal treatment of herpes infections. They have a number of disadvantages, in particular formation of the virus resistance in a long-term use, the need to involve immunotherapy, as well as the high cost of treatment. The accumulated clinical experience with the original Ukrainian drug Proteflazid® (drops) in treating viral infections, including HHV- infections, shows its high clinical efficacy and safety. A relative estimation of the course treatment costs of herpes-induced infections using antiviral drugs has demonstrated the economic expediency of Proteflazid® with the purpose of treatment and maintenance therapy. Proteflazid® takes the medium sized niche among other antiherpetic drugs. In addition, due to the multi-vector nature of its pharmacodynamic effects (direct antiviral, immunomodulating, interferon-stimulating, antioxidant, apoptosis-modulating, etc.) Proteflazid® allows to exclude antioxidants, immunomodulators from the antiherpetic therapy scheme, or to adjust their use, and it can significantly reduce the cost per a course of treatment.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The assortment analysis of chlorhexidine-containing medicines and procurement data of state and municipal organizations Laboratory toxicological diagnosis of trazodone intoxications The analysis of approaches to conducting bioequivalence studies and the policy of “transparency” of their results in Ukraine, the United States and the European Union Subunit compositions of GABAA receptors determining the diversity of physiological processes and neurotropic properties of medicines Ways of medicinal prevention and treatment of doxorubicin-induced cardiomyopathy in oncological patients
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1